Generic Medicine Info
Indications and Dosage
Supraventricular arrhythmias
Adult: Initially, 5-10 mg via slow inj over 2-3 minutes then 5 mg via inj after 5-10 minutes if needed.
Child: ≤1 years 0.1-0.2 mg/kg; 1-15 years 0.1-0.3 mg/kg (Max: 5 mg). All doses to be given over at least 2 minutes, repeat after 30 min if needed.

Angina pectoris
Adult: 120 mg tid or 80 mg tid in patients w/ angina of effort. As modified-release: Up to 480 mg daily.

Supraventricular arrhythmias
Adult: 120-480 mg daily in 3-4 divided doses depending on patient's response and severity of the condition.
Child: ≤2 yr 20 mg 2-3 times daily; >2 yr 40-120 mg 2-3 times daily, depending on age and response.

Adult: Initially, 240 mg daily in 2-3 divided doses. Max: 480 mg daily.
Child: ≤2 yr 20 mg 2-3 times daily; >2 yr 40-120 mg 2-3 times daily, depending on age and response.

Secondary prophylaxis of myocardial infarction
Adult: Modified release: Initially, 360 mg daily in divided doses 1 wk after acute infarction.
Hepatic Impairment
Severe: Reduce dose by up to 60-70%.
Should be taken with food.
Y-site: Ampothericin B cholesteryl sulfate complex, nafcillin, ampicillin, oxacillin, albumin, pantoprazole, Na bicarbonate.
Cardiogenic shock, hypotension (systolic pressure <90 mmHg), marked bradycardia, uncompensated heart failure, 2nd- or 3rd-degree AV block (unless pacemaker is fitted), sick-sinus syndrome, severe ventricular dysfunction, atrial flutter or atrial fibrillation and accessory bypass tract (e.g. Wolff-Parkinson-White, Lown-Ganong-Levine syndromes).
Special Precautions
Patient w/ bradycardia or 1st-degree AV block, attenuated neuromuscular transmission, hypertrophic cardiomyopathy. Avoid abrupt withdrawal. Renal and hepatic impairment. Childn. Pregnancy and lactation.
Adverse Reactions
AV block, bradycardia, worsening heart failure, transient asystole, hypotension, dizziness, flushing, fatigue, headache, dyspnoea, peripheral oedema, constipation, nausea, abnormal liver function, skin reactions, gingival hyperplasia, extrapyramidal symptoms. Rarely, gynaecomastia.
Potentially Fatal: Hepatotoxicity.
IV/Parenteral/PO: C
Monitoring Parameters
Monitor BP, heart rate, ECG, LFTs (periodically).
Symptoms: Bradycardia, hypotension, conduction abnormalities, hyperglycaemia, hyperkalaemia, metabolic acidosis, renal dysfunction, seizures, impaired conduction, ECG changes, arrhythmias, shock, altered mental status, cardiac arrest. Management: Symptomatic and supportive treatment. Place patient Trendelenburg's position and admin IV fluids. Hypotension may be treated w/ IV Ca salts or vasopressor agent. Bradycardia or fixed 2nd- or 3rd-degree AV block may be treated w/ norepinephrine, IV atropine, isoproterenol, Ca salt or a temporary cardiac pacemaker. Consider endoscopy in cases of large overdoses.
Drug Interactions
May increase plasma level w/ CYP3A4 inhibitors (e.g. erythromycin, ritonavir), cimetidine. May decrease plasma level w/ CYP3A4 inducers (e.g. rifampicin), phenobarbital, sulfinpyrazone. Increased risk of bleeding w/ aspirin. May increase bradycardic and hypotensive effect w/ telithromycin. Increased AV blocking effect w/ clonidine. May increase plasma level of cardiac glycosides (e.g. digoxin, digitoxin), β-blockers (e.g. propranolol, metoprolol), α-blockers (e.g. terazosin, prazosin), immunosuppressants (e.g. sirolimus, ciclosporin, tacrolimus, everolimus), lipid lowering agents (e.g. lovastatin, simvastatin, atorvastatin), colchicines, quinidine, carbamazepine, imipramine, glibenclamide, doxorubicin, midazolam, buspirone, almotriptan, theophylline. May potentiate hypotensive effect w/ diuretics, antihypertensives, vasodilators. May increase neurotoxic effect of lithium.
Food Interaction
Increased plasma levels w/ grapefruit juice. May increase plasma level of alcohol. Decreased plasma levels w/ St John's wort.
Lab Interference
May cause false-positive result w/ urine detection of methadone.
Mechanism of Action: Verapamil inhibits entry of Ca ions into the slow channels or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarisation. It relaxes coronary vascular smooth muscle and coronary vasodilation, increases myocardial oxygen delivery, and slows automaticity and AV node conduction.
Onset: W/in 1-2 hr (oral); w/in 5 min (IV).
Duration: 6-8 hr (oral); 10-20 min (IV).
Absorption: Absorbed from the GI tract approx 90%. Bioavailability: 20-35% (oral). Time to peak plasma concentration: 1-2 hr (oral).
Distribution: Crosses the placenta; enters breast milk. Volume of distribution: 3.89 L/kg. Plasma protein binding: Approx 90%.
Metabolism: Extensively metabolised hepatically to at least 12 metabolites (e.g. norverapamil as primary metabolites).
Excretion: Via urine (70% as metabolites, 3-4% as unchanged drug); faeces (16%). Terminal half-life: 2-8 hr; increases to 4.5-12 hr (after oral repeated dose).
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Verapamil, CID=2520, (accessed on Jan. 23, 2020)

Store between 15-30°C. Protect from light.
MIMS Class
Calcium Antagonists
ATC Classification
C08DA01 - verapamil ; Belongs to the class of phenylalkylamine derivative selective calcium-channel blockers with direct cardiac effects. Used in the treatment of cardiovascular diseases.
Anon. Verapamil. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 21/11/2014.

Buckingham R (ed). Verapamil Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 21/11/2014.

Calan Tablets. U.S. FDA. Accessed 21/11/2014.

Isoptin SR Tablet, Coated (Abbott Laboratories). DailyMed. Source: U.S. National Library of Medicine. Accessed 21/11/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Verapamil Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 21/11/2014.

Verelan Capsules and Verelan PM Extended-Release Capsules. U.S. FDA. Accessed 21/11/2014.

Disclaimer: This information is independently developed by MIMS based on Verapamil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
  • Verpamil
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in